Gilead Sciences is a research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company's primary focus is on therapies for life-threatening infectious diseases, particularly HIV/AIDS and hepatitis B and C. Gilead's portfolio includes the hepatitis C drug Sovaldi, which emerged from its acquisition of Pharmasset, and is part of established combination treatment regimens. Additionally, Gilead is expanding its presence in oncology through strategic acquisitions, including CAR-T cell therapies such as Yescarta and Tecartus, as well as breast and bladder cancer treatments like Trodelvy. By concentrating on these critical areas, Gilead aims to enhance patient care and outcomes for those with serious health conditions.
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
The Children’s Inn at NIH enhances the opportunities for groundbreaking medical discoveries by providing a free “place like home” that reduces the burdens of illness through a supportive environment that includes therapeutic, educational, and recreational programming for children.
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
Leap Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing targeted and immuno-oncology therapies for cancer treatment. Founded in 2011, the company primarily focuses on acquiring and advancing therapies that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1), currently undergoing clinical trials for various cancers, including esophagogastric, gynecologic, and colorectal cancers. Additionally, Leap Therapeutics is developing FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at creating transformative cancer treatments.
SisterLove is a foundation located in Atlanta, Georgia, founded in 1989. Its mission is to address and eradicate the negative effects of HIV/AIDS and other reproductive health challenges that disproportionately affect women and their families. The organization focuses on education, prevention, support, research, and advocacy for health rights and justice, both in the United States and globally. SisterLove is dedicated to empowering women by providing essential resources and promoting awareness about reproductive health issues.
A New Way of Life Reentry Project is a non profit organization that provides housing and reentry support to formerly incarcerated women and their children. A New Way of Life operates a total of four sober living homes, serving 40-50 women and children per year, and offers a wide range of support services to help facilitate a successful transition back to community life. Since its founding in 1998, A New Way of Life has helped transform the lives of over 220 women.
Transinclusive Group is a Transgender-Led TLGBQ+ tax exempt, non-profit organization. As an advocacy driven organization, its goal is to cultivate advocates to take action to influence social, political, and economic systems to bring about change for all TLGBQ+ individuals.
Ribbon is a Center of Excellence that specializes in skill-building training and technical assistance, long-term organizational development, and leadership development.
SLK is a community- based health care organization. It promotes the prevention and eradication of illnesses and infections among vulnerable communities, especially high-risk negatives and the LGBTQ community.
Triumphant 2Gether is a tax-exempt, nonprofit organization. It empowers women and girls impacted by violence through policy advocacy and social service projects.
WeCareTn is a non-profit organization build to support transwomen. It supports Transwomen of color through education and empowerment with the goal that they have the same equity and quality of life as envisioned.
Howard University, located in Washington, D.C., is an esteemed institution founded in 1867 that emphasizes educational opportunities for African-American students. It offers a range of programs at the undergraduate, graduate, and doctoral levels, including fields such as law, medicine, and pharmaceutical studies. The university is committed to providing a high-quality educational experience for students of strong academic potential. Additionally, it manages an endowment fund that supports various initiatives, including scholarships, professorships, and student loans. The assets of this endowment are overseen by the university's executive management team, ensuring effective allocation to support its mission and operations.
The California Black Women's Health Project is the only statewide, non-profit organization that is solely committed to improving the health of California's 1.2 million Black women and girls through advocacy, education, outreach and policy.
BWLI is a national institute at NDRI-USA Inc., a not-for-profit research and development organization which provides high-impact actionable solutions to pressing public health problems. Its mission is to improve health and wellness for Black women across the lifespan through innovative resources, programmatic support, and culturally-relevant public health education.
WACO Theater Center
Grant in 2024
WACO (Where Art Can Occur) Theater Center is a cultural institution that promotes modern African Diaspora performing and visual arts.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.
Alliance of AIDS Services provides health care services. They provide resources and charitable services for AIDS patients. They improve the health of communities impacted by HIV/AIDS through compassionate and non-judgmental prevention, support services, and connection to care.
MBK's objective is to improve the health and well-being of minority and marginalized people across the United States by providing leadership and engagement with the public and community healthcare providers. The HIV prevention services provided by MBK centered on developing and delivering a diverse set of educational and training programs in public health, social policy, action research, information technology, advocacy, coalition development, and capacity building. MBK built its dedication to HIV prevention among racial and ethnic minority communities through its significant expertise, as seen by its service to over 15,000 clients nationwide.
Central Illinois Friends provides compassionate and personalized care to people living with HIV and vulnerable community members who require comprehensive clinical and supportive services.
Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.
Nueva vida goal is to educate, encourage, and empower Latinas whose lives are impacted by cancer. Nueva vida also works to promote timely access to cutting-edge cancer treatment.
Young Survival Coalition is engaged in the critical issues unique to young women and breast cancer. They work with survivors, caregivers, medical, research, advocacy, and legislative communities to increase the life expectancy for women diagnosed with breast cancer. They also produce free educational resources, such as the breast cancer navigator series, which are comprehensive guidebooks that address every phase of treatment and survivorship.
MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.
Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics.
Curebase is a company that develops software aimed at transforming the management of clinical trials. Founded in 2017 and based in San Francisco, California, its platform facilitates faster and more cost-effective trial execution by streamlining participant eligibility, enrollment, education, and consent processes. The software automates many manual steps and allows drug companies to efficiently distribute their trials to clinics. Additionally, it provides sponsors with access to real-time data, enabling them to monitor trial progress and manage information effectively. Curebase's services cater to various sectors, including medical devices, biotechnology, and digital health startups, enhancing the overall efficiency of clinical research.
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.
Destination Tomorrow is the Black-led Transgender & Gender Non-Conforming (TGNC) grant-making agency. The Destination Tomorrow offers services that take LGBTQ/TGNC individuals off the path of requiring emergency care with a focus on economic, social and mental empowerment on a holistic level.
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company's proprietary platform includes modified simian adenoviral vectors known as ChAdOx1 and ChAdOx2, as well as a Modified Vaccinia Ankara (MVA) boost vector, both of which have established safety profiles and do not replicate in humans. This platform has shown to elicit significantly higher levels of CD8+ T cells compared to other technologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs addressing solid tumors and viral infections, alongside prophylactic vaccine candidates. The company has also collaborated on the development of a COVID-19 vaccine in partnership with the University of Oxford, which has been licensed for global use.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.
MYR Group is a holding company that specializes in electrical construction services, primarily serving the electrical infrastructure and commercial/industrial markets across the United States and Canada. The company operates through a network of local offices and encompasses several subsidiaries, including The L.E. Myers Co., Sturgeon Electric Company, and Harlan Electric Company, among others. MYR Group's services include the design, engineering, procurement, construction, and maintenance of transmission and distribution systems, as well as commercial wiring and traffic network installations. With a highly skilled workforce and an extensive fleet of specialized equipment, MYR Group is recognized for its commitment to customer service and continuous improvement in the electrical industry.
Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.
The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative cancer immunotherapies. Founded in 2015, the company aims to enhance the body's antitumor immunity by targeting the tumor microenvironment. Utilizing advanced target discovery and antibody generation technologies, Pionyr has created a unique approach called Myeloid Tuning™, which modifies the cellular infiltrate within tumors to improve the immune system's response against cancer. This strategy is intended to be particularly effective when used in conjunction with checkpoint inhibitors, offering new avenues for cancer treatment.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.
Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.
Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.
The National AIDS Memorial relies solely on funding from longtime personal donors and corporate partners to support its mission as a dedicated space in the national landscape where millions of Americans touched directly or indirectly by AIDS can gather to heal, hope, and remember. The National AIDS Memorial, known as “the Grove”, was created more than twenty-eight years ago in San Francisco’s Golden Gate Park at the height of the HIV/AIDS epidemic as a place where those impacted by AIDS could both grieve and begin the process of healing. In 1996, legislation sponsored by U.S. Representative Nancy Pelosi was signed into law by President Clinton that elevated “the Grove” as this nation's sole federally-designated National AIDS Memorial. More than 50,000 individuals from around the world have contributed 225,000 volunteer hours to support the National AIDS Memorial and its mission.
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.
Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.
AlloVir is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. Its lead product, Viralym-M, targets multiple viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline includes several candidates in various stages of development, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2 and COVID-19, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. AlloVir was founded in 2013 and was formerly known as ViraCyte, Inc. The company is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases through its proprietary VST therapy platform.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.
Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.
Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, focused on developing innovative cell-based therapies for cancer and other serious diseases. Established in 2015, the company aims to harness the immune system's capabilities to create advanced treatments that offer improved power, precision, safety, and durability. Cell Design Labs specializes in disruptive T cell receptor therapies, which modify the body's immune cells to specifically recognize and eliminate malignant cells. This approach enables researchers to efficiently develop effective cell-based therapies that address some of the most challenging medical conditions. The company operates as a subsidiary of Gilead Sciences, Inc.
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.
EpiTherapeutics is dedicated to developing innovative cancer therapies through the exploration of epigenetics, a field advanced by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen. The company focuses on small-molecule therapies, specifically targeting enzymes that regulate transcription in cancerous cells. EpiTherapeutics has established a library of selective small molecule inhibitors aimed at epigenetic regulation, particularly histone demethylases. Its lead pre-clinical compounds are currently being investigated for their potential effectiveness in treating various forms of cancer.
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002 and headquartered in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, focusing on nuclear receptors to address various disease areas, including liver diseases, intestinal diseases, and cancer. Current research includes developing RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. Phenex is dedicated to not only creating therapeutics for established targets but also identifying novel molecular mechanisms, which has led to the development of proprietary therapeutic small molecules. The company operates within the Biotech Cluster Rhine-Neckar, leveraging its expertise in biology and chemistry to advance innovative treatment options.
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Arresto Biosciences, Inc., a biotechnology company, develops medicines to treat cancer and fibrotic diseases by targeting molecules from the extracellular matrix. The company was incorporated in 2007 and is based in Palo Alto, California.
Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000. CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function. CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise. Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI). To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors. Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library.
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
Nycomed Limited, formerly known as Altana Pharma Limited. Nycomed Limited has been conducting manufacturing and tabletting operations at the Cork facility.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. They believe that our advanced understanding of the biology of cardiovascular disease combined with their clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Triangle Pharmaceuticals
Acquisition in 2003
Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.
NeXstar Pharmaceuticals
Acquisition in 1999
NeXstar Pharmaceuticals is a Pharmaceutical company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.